Increased production of HDL ApoA-I in homozygous familial defective ApoB-100

被引:15
作者
Schaefer, JR
Winkler, K
Schweer, H
Hoffmann, MM
Soufi, M
Scharnagl, H
Maisch, B
Wieland, H
Steinmetz, A
März, W
机构
[1] Univ Freiburg, Dept Med, Div Clin Chem, D-79106 Freiburg, Germany
[2] Univ Marburg, Dept Internal Med, Div Cardiol, D-3550 Marburg, Germany
[3] Univ Marburg, Childrens Hosp, Marburg, Germany
关键词
hypercholesterolemia; reverse cholesterol transport; tracer kinetics; stable isotopes;
D O I
10.1161/01.ATV.20.7.1796
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Familial defective apolipoprotein (apo) B-100 (FDB) is a frequent cause of hypercholesterolemia. Hypercholesterolemia in homozygous FDB is less severe than in homozygotes for familial hypercholesterolemia. Recently, we showed decreased low density lipoprotein (LDL) apoB-100 fractional catabolism and decreased production of LDL due to an enhanced removal of apoE-containing precursors in a patient with homozygous FDB. The effects of defective apoB-100 on high density lipoprotein (HDL) metabolism are unknown. We studied HDL apoA-I metabolism in this FDB patient and in 6 control subjects by using H-2(3)-L-leucine as a tracer. ApoA-I levels were normal in all study subjects. However, the fractional catabolic rate and the production rate of apoA-I were increased, by 79% and 70%, respectively, in FDB; the fractional catabolic rate of apoA-I in FDB was 0.34 day(-1) compared with 0.19 +/- 0.03 day(-1) in normal controls. The production rate of apoA-I in FDB was 18.4 mg(.)kg(-1.)d(-1) compared with 10.8 +/- 2.3 mg(.)kg(-1.)d(-1) in controls. Thus, we have shown for the first time that defective apoB-100 may influence HDL kinetics, The increase in total HDL turnover might enhance reverse cholesterol transport and could contribute to the seemingly benign clinical course of FDB compared with that of familial hypercholesterolemia.
引用
收藏
页码:1796 / 1799
页数:4
相关论文
共 22 条
[11]   THE EFFECT OF THE HMG-COA REDUCTASE INHIBITOR SIMVASTATIN AND OF CHOLESTYRAMINE ON HEPATIC APOLIPOPROTEIN MESSENGER-RNA LEVELS IN THE RAT [J].
MITCHELL, A ;
FIDGE, N ;
GRIFFITHS, P .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1167 (01) :9-14
[12]  
Pietzsch J, 1996, J LIPID RES, V37, P2074
[13]   VERY-LOW HIGH-DENSITY-LIPOPROTEINS WITHOUT CORONARY ATHEROSCLEROSIS [J].
RADER, DJ ;
IKEWAKI, K ;
DUVERGER, N ;
FEUERSTEIN, I ;
ZECH, L ;
CONNOR, W ;
BREWER, HB .
LANCET, 1993, 342 (8885) :1455-1458
[14]   INCREASED PRODUCTION OF APOLIPOPROTEIN-A-I ASSOCIATED WITH ELEVATED PLASMA-LEVELS OF HIGH-DENSITY-LIPOPROTEINS, APOLIPOPROTEIN-A-I, AND LIPOPROTEIN-A-I IN A PATIENT WITH FAMILIAL HYPERALPHALIPOPROTEINEMIA [J].
RADER, DJ ;
SCHAEFER, JR ;
LOHSE, P ;
IKEWAKI, K ;
THOMAS, F ;
HARRIS, WA ;
ZECH, LA ;
DUJOVNE, CA ;
BREWER, HB .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (11) :1429-1434
[15]   INVIVO METABOLISM OF APOLIPOPROTEIN-A-I IN A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
SCHAEFER, JR ;
RADER, DJ ;
IKEWAKI, K ;
FAIRWELL, T ;
ZECH, LA ;
KINDT, MR ;
DAVIGNON, J ;
GREGG, RE ;
BREWER, HB .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (07) :843-848
[16]   Homozygous familial defective apolipoprotein B-100 - Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs [J].
Schaefer, JR ;
Scharnagl, H ;
Baumstark, MW ;
Schweer, H ;
Zech, LA ;
Seyberth, H ;
Winkler, K ;
Steinmetz, A ;
Marz, W .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (02) :348-353
[17]   Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease [J].
Schaefer, JR ;
Schweer, H ;
Ikewaki, K ;
Stracke, H ;
Seyberth, HJ ;
Kaffarnik, H ;
Maisch, B ;
Steinmetz, A .
ATHEROSCLEROSIS, 1999, 144 (01) :177-184
[18]  
Scharnagl H, 1997, Expert Opin Investig Drugs, V6, P583, DOI 10.1517/13543784.6.5.583
[19]  
SCHARNAGL H, IN PRESS ATHEROSCLER
[20]  
Schweer H, 1996, J MASS SPECTROM, V31, P727